It is premature to consider kisspeptin-54 as a therapeutic for HA; however, one potential advantage of administering kisspeptin-54 over GnRH would be its suitability for constant pump administration, which is increasingly used to deliver insulin therapy to certain patients with diabetes (42). This evidence concerns the gene GNRH1 and diabetes mellitus.